However, sustained NRF2 activation drives hepatic pathology through lipogenic promotion, suppressed lipolysis, pro-tumorigenic p62 interactions, and cancer-associated metabolic reprogramming 19, 32-35. This evidence concerns the gene NFE2L2 and cancer.